TrivarX Ltd. engages in clinical research, product development, and early-stage commercialization of mental health technology. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-01-29. Through the Company’s corporate health product, it offers mental well-being solutions for businesses and is also developing products to serve the healthcare provider market. The principal activity of the Company is development of artificial intelligence (AI)-driven, scientifically based devices for screening and diagnosis of behavioral health conditions. Its clinical research has enabled the development of proprietary algorithms for spectral analyses of sleep architecture and heart-rate variability. The Company’s lead product, MEB-001 analyses the data from a standard sleep study to identify depression at a sensitivity of over 85%. Its technology analyses the electrical signals from the brain and the heart to identify mental illness.
How did MDBIF's recent EPS compare to expectations?
The most recent EPS for TrivarX Ltd is $, expectations of $.
How did TrivarX Ltd MDBIF's revenue perform in the last quarter?
TrivarX Ltd revenue for the last quarter is $
What is the revenue estimate for TrivarX Ltd?
According to of Wall street analyst, the revenue estimate of TrivarX Ltd range from $ to $
What's the earning quality score for TrivarX Ltd?
TrivarX Ltd has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does TrivarX Ltd report earnings?
TrivarX Ltd next earnings report is expected in 2026-05-27
What are TrivarX Ltd's expected earnings?
TrivarX Ltd expected earnings is $, according to wall-street analysts.